+91-8826806862 Home About Us Courses Research Publications CRO Services Career Contact Us Clinical Research Training 12000+ Alumni, 500+ Cities, 30+ Countries and counting SPECIALIZED CLINICAL RESEARCH, GCP &PHARMACOVIGILANCE COURSES India's largest Clinical Research & PVG Training Providers View Details...
The COVID-19 pandemic altered the way patients everywhere access and receive care. The use of direct-to-patient channels such as at-home disease monitoring, medicine home delivery services and telehealth grew dramatically, improving health equity by benefitting patients who are less mobile...
Does a drug work and is it safe? It touches on almost every aspect of the drug lifecycle - from preclinical development to post-market surveillance - making it one of the most fundamental functions within a life science company. Within this blog, we have looked closely at the importance of...
The globalpharmacovigilance market sizewas estimated at USD 7.32 billion in 2023and is anticipated to grow at a CAGR of 6.8% from 2024 to 2030. The rising incidence of Adverse Drug Reactions (ADRs) owing to drug abuse and the prevalence of diseases that require a combination of drugs are the...
HOME Top Market Reports Drug Safety and Pharmacovigilance Software Market Drug Safety and Pharmacovigilance Software Market by Functionality (Adverse Event Reporting, Fully Integrated Software), Delivery Mode (On-premise, On-demand/Cloud based (SAAS)), End-user (Pharma & Biotech Companies, CR...
Home About Us Our Services Pharmaceutical Regulatory Services Product Registration in China INDs, NDAs, ANDAs Registration in China Drug Master File (DMF) Filling in China (APIs, Excipients, Packaging) eCTD Submission in China Regulatory Advisory Regulatory Intelligence Dossier Compliance Assessment and ...
with the COVID-19 pandemic, many companies launched new issue-tracking software to better serve patients. For instance, in May 2021, Dialog Solutions introduced the next generation of pharmacovigilance literature monitoring: Drug Safety Triager. Thus, the launch of such a product may work in the...
compared to control using the raw data presented by Nissen et al and Home et al (Fixed effects, RevMan 4.2). However, the combined result is an increase of myocardial infarction with Rosiglitazone that can be described as a Risk Difference of 0.0024 (95% confidence interval 0.0002 to 0.0045...
You are here: Home Pharmaceutical Pharmacovigilance (PV) in China Bylavinia March 13, 2021 Pharmaceutical Before 2018, the Pharmacovigilance (PV) System in China was still in its early days. Companies’ activities to drug safety were for the most part passive. ...
In June 2024, IQVIA introduced a home clinical technology trial platform, addressing site challenges and reducing workload. This technology enabled sites to streamline recruitment and treatment processes, increasing patient enrollment capacity and concurrent trial management. In February 2023, Labcorp...